Navigation Links
Rigel's R788 Phase 2a Results Published in Arthritis and Rheumatism
Date:11/11/2008

First of Phase 2b studies completes patient screening for enrollment

SOUTH SAN FRANCISCO, Calif., Nov. 11 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that the previously reported results of the Phase 2 clinical trial of R788 (fostamatinib disodium), the company's oral Syk inhibitor, have been published in the November 2008 issue of Arthritis and Rheumatism. The article, entitled, "Treatment of rheumatoid arthritis with a syk kinase inhibitor: A twelve-week, randomized, placebo-controlled trial" was written by Michael E. Weinblatt, M.D., et al.

The investigators for this study, also called TASKi1, which enrolled 189 patients with active rheumatoid arthritis (RA) already taking methotrexate for their disease, found that the 100 mg and 150 mg doses of R788 showed rapid and significant improvement in patient outcomes as measured by ACR 20, ACR 50 and ACR 70 response scores. The adverse events reported were manageable and, in large part, reversible by reduced dosing or stoppage of drug. The investigators concluded that R788 may offer a new therapeutic option for patients with RA and that additional clinical studies were warranted.

Phase 2b update

In June 2008, Rigel initiated two Phase 2b trials of R788 in patients with RA, TASKi2 and TASKi3, to further explore the safety and efficacy of the drug candidate in a larger number of patients over a longer time period in multiple centers in North America, Latin America and Europe. "At this time, we are pleased to report that we have successfully completed patient screening for enrollment in TASKi2 and are proceeding with both Phase 2b trials on schedule," commented Elliott Grossbard, M.D., executive vice president and chief medical
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cell Therapeutics Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint
2. Anesiva Announces Adlea ACTIVE-1 Phase 3 Clinical Results, Ceasing of Zingo Commercial Operations and Restructuring
3. Raptor Pharmaceuticals to Collaborate with Centre Hospitalier Universitaire dAngers for Phase II Clinical Trial in Huntingtons Disease
4. VIA Pharmaceuticals Announces Positive Results of Phase 2 Studies of VIA-2291 in Patients With Serious Cardiovascular Disease
5. Patient Recruitment Begins in India for Phase 3 Diabetes Trial
6. Portola Announces Data Presentations Relevant to Its Lead Phase II Antithrombotic Compounds at American Heart Association Scientific Sessions 2008
7. Poniard Pharmaceuticals Announces Final Top-Line Results from Phase 1 Trial Demonstrating Positive Bioavailability with Oral Picoplatin
8. Bavarian Nordic Reports Successful Safety Data From Phase II Study With IMVAMUNE(R)
9. VIA Pharmaceuticals Announces Conference Call and Webcast to Discuss VIA-2291 Phase 2 Data Presentations at AHA
10. Bionovo Advances BZL101 to Phase 2 Clinical Trials After Positive Phase 1 Results for Metastatic Breast Cancer
11. MedImmune Advances Pediatric Disease Prevention Program With Start of Phase 1/2a Clinical Trial for Respiratory Syncytial Virus Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... and BEDFORD, Mass. , ... Arroyo LLP is investigating whether certain officers ... Securities and Exchange Act of 1934.  ConforMIS is a ... platform to develop, manufacture, and sell joint replacement implants ... patient,s unique anatomy. View this press release ...
(Date:9/1/2015)... Delaware , United States ... "Company" or "Invion"), is pleased to announce that it has ... an institutional investor in the United States ... approximately A$1.001 million ("Placement") by the issue of 71,500,000 million ... per share. The Company has also agreed ...
(Date:9/1/2015)... and OR YEHUDA, Israel , Sept. ... HTWR ), a leading innovator of less invasive, ... of advanced heart failure, announced today that it has ... Cardio, Ltd . ("Valtech").  Valtech is a privately held ... and transcatheter valve repair and replacement devices for the ...
Breaking Medicine Technology:Robbins Arroyo LLP Is Investigating the Officers and Directors of ConforMIS, Inc. (CFMS) on Behalf of Shareholders 2Invion Announces Private Placement to US Institutional Investor 2Invion Announces Private Placement to US Institutional Investor 3HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 2HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 3HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 4HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 5HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 6HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 7HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 8HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 9HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 10
... 2011 Visionary Pharmaceuticals, Inc., announced today that ... a consortium of Angel Investors. The company is ... retinoic acid related orphan receptor (ROR) modulators targeting ... disorders including rheumatoid arthritis, multiple sclerosis, psoriasis and ...
... Ind., July 26, 2011 Symmetry Medical Inc. (NYSE: ... the global orthopaedic device industry and other medical markets, announced ... for the period ending July 2, 2011 before the market ... an accompanying conference call at 8:00 a.m. ET on Thursday, ...
Cached Medicine Technology:Visionary Pharmaceuticals, Inc., Announces Initial Seed Round Investments and the Launch of TH17 Autoimmune Disease Research Activities 2Symmetry Medical to Report Second Quarter 2011 Financial Results on August 4, 2011 2
(Date:9/2/2015)... , ... September 02, 2015 , ... Ericson is a ... Education Director for HCPro and Associate Director of Education for the Association for Clinical ... CDI and ICD-10 for CDI Boot Camps. She serves as a CDI subject matter ...
(Date:9/2/2015)... ... ... Every year at this time, students prepare to go back to school. ... the academic workload confronting them. They just don’t have the skills needed to do ... students how to study. , “Bankers bank. Salesmen sell. Teachers teach. The job of ...
(Date:9/2/2015)... City, KS (PRWEB) , ... September 02, 2015 , ... ... opened its newest office in Kansas – its Johnson County location. Amada ... in healthcare. Mike has a registered nurse background and spent over 20 years in ...
(Date:9/2/2015)... North Las Vegas, NV (PRWEB) , ... September ... ... in Las Vegas and Fort Lauderdale, CENTURION SERVICE GROUP is internationally known as ... the largest medical auction house in the world, selling more than 100,000 pieces ...
(Date:9/2/2015)... ... 02, 2015 , ... On September 9, 2015, over 27,000 people from all ... single-company convention to date for the state of Utah. , “We are thrilled with ... states David Stirling, doTERRA CEO. “One of the most exciting elements of our convention ...
Breaking Medicine News(10 mins):Health News:ezDI Names Noted CDI Educator Cheryl Ericson as Company’s Clinical Documentation Manager 2Health News:ezDI Names Noted CDI Educator Cheryl Ericson as Company’s Clinical Documentation Manager 3Health News:ezDI Names Noted CDI Educator Cheryl Ericson as Company’s Clinical Documentation Manager 4Health News:5 Essential Study Tips Every Student Needs for Academic Success but Schools Do Not Teach 2Health News:5 Essential Study Tips Every Student Needs for Academic Success but Schools Do Not Teach 3Health News:Amada Senior Care Expands to Greater Kansas City 2Health News:Over 1800 Lots of Surplus Used Medical Equipment 2Health News:Over 1800 Lots of Surplus Used Medical Equipment 3Health News:doTERRA to Host the Largest Single-Company Convention in the State of Utah 2
... Dec. 1 The Kerlan Jobe Orthopaedic Clinic, a sports ... United States $3 million to settle allegations that it received ... , The settlement resolves allegations ... of stock option grants, donations to the Kerlan Jobe Foundation, ...
... A scientist who broadened the understanding of how we experience ... -- has won the 2010 University of Louisville Grawemeyer Award ... University in Montreal, was selected for the award from among ... of injury but instead in their brain through a pathway ...
... more likely, British study finds , TUESDAY, Dec. 1 (HealthDay ... to deliver a very preterm baby than more affluent women, ... British study shows. , The University of Leicester research team ... the association between economic status and preterm birth. , For ...
... on computed tomography (CT) imaging of changes in tumors ... bevacizumab may have the potential to predict overall survival, ... of JAMA . The addition of ... with improved survival in patients with stage IV colorectal ...
... ... ... largest national HIV non-profit organizations, is changing its name to HealthHIV and launching a new ... promote the organization’s new vision and expanded capabilities and reach. , , , , ,“HealthHIV ...
... With employee benefit choices becoming more complex, a growing ... during open enrollment season, according to a new survey by ... employers who offer these tools believe they lead employees to ... survey, 45 percent of companies offered employees self-service decision tools ...
Cached Medicine News:Health News:Los Angeles' Kerlan Jobe Orthopaedic Clinic Pays $3 Million to Settle Kickback Allegations 2Health News:Scientist Who Helps Explain Pain Wins Grawemeyer Award 2Health News:More Preemies Born Among the Poor 2Health News:Criteria based on CT imaging after chemotherapy may help predict survival 2Health News:National HIV Non-Profit Announces New Name 2Health News:Employers Plan to Increase Use of Self-Service Decision-Making Technology For Open Enrollment, Watson Wyatt Survey Finds 2Health News:Employers Plan to Increase Use of Self-Service Decision-Making Technology For Open Enrollment, Watson Wyatt Survey Finds 3
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
... AEM Laparoscopic Instruments incorporate a layered design ... shielded and monitored to prevent stray electrosurgical ... caused by insulation failure or capacitive coupling; ... shield built into all AEM Instruments provides ...
... Instruments incorporate a layered design unique in ... monitored to prevent stray electrosurgical burns along ... insulation failure or capacitive coupling; a well-documented ... into all AEM Instruments provides a neutral ...
Medicine Products: